nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions
|
Opriessnig, Tanja |
|
|
35 |
2 |
p. 248-254 |
artikel |
2 |
Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia
|
Reyes, J.F. |
|
|
35 |
2 |
p. 345-352 |
artikel |
3 |
Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep
|
van Rijn, Piet A. |
|
|
35 |
2 |
p. 231-237 |
artikel |
4 |
Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis
|
Young, Barnaby |
|
|
35 |
2 |
p. 212-221 |
artikel |
5 |
Editorial Board/Aims and Scope
|
|
|
|
35 |
2 |
p. IFC |
artikel |
6 |
Effect of seasonal vaccination on the selection of influenza A/H3N2 epidemic variants
|
Chong, Yong |
|
|
35 |
2 |
p. 255-263 |
artikel |
7 |
Efficacy and safety of an inactivated vaccine against Salmonid alphavirus (family Togaviridae) [Vaccine 30 (2012) 5688–5694]
|
Grisez, Luc |
|
|
35 |
2 |
p. 203 |
artikel |
8 |
Efficacy of the GMZ2 malaria vaccine in African children
|
Milligan, Paul |
|
|
35 |
2 |
p. 202 |
artikel |
9 |
Flagellin enhances the immunoprotection of formalin-inactivated Edwardsiella tarda vaccine in turbot
|
Liu, Xiaohong |
|
|
35 |
2 |
p. 369-374 |
artikel |
10 |
gp85 protein vaccine adjuvanted with silica nanoparticles against ALV-J in chickens
|
Cheng, Jia |
|
|
35 |
2 |
p. 293-298 |
artikel |
11 |
Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion
|
Pilkinton, Mark A. |
|
|
35 |
2 |
p. 329-336 |
artikel |
12 |
Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization
|
Moseri, Adi |
|
|
35 |
2 |
p. 222-230 |
artikel |
13 |
Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation
|
Datta, Dibyadyuti |
|
|
35 |
2 |
p. 264-272 |
artikel |
14 |
Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens
|
Maruggi, Giulietta |
|
|
35 |
2 |
p. 361-368 |
artikel |
15 |
Immunogenicity and protective efficacy of a single-dose live non-pathogenic Escherichia coli oral vaccine against F4-positive enterotoxigenic Escherichia coli challenge in pigs
|
Fairbrother, John Morris |
|
|
35 |
2 |
p. 353-360 |
artikel |
16 |
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults
|
Song, Joon Young |
|
|
35 |
2 |
p. 313-320 |
artikel |
17 |
Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection
|
de Vries, Rory D. |
|
|
35 |
2 |
p. 238-247 |
artikel |
18 |
Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country
|
Akhtar, Marjahan |
|
|
35 |
2 |
p. 321-328 |
artikel |
19 |
Knowledge and attitudes towards influenza vaccination of health care workers in emergency services
|
Hulo, Sébastien |
|
|
35 |
2 |
p. 205-207 |
artikel |
20 |
Maternal BCG scar is associated with increased infant proinflammatory immune responses
|
Mawa, Patrice Akusa |
|
|
35 |
2 |
p. 273-282 |
artikel |
21 |
Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England
|
Christensen, Hannah |
|
|
35 |
2 |
p. 208-211 |
artikel |
22 |
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial
|
Iro, Mildred A. |
|
|
35 |
2 |
p. 395-402 |
artikel |
23 |
Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand
|
Chotpitayasunondh, Tawee |
|
|
35 |
2 |
p. 299-304 |
artikel |
24 |
Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine
|
Poore, Elizabeth A. |
|
|
35 |
2 |
p. 283-292 |
artikel |
25 |
Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach
|
Pan-Ngum, Wirichada |
|
|
35 |
2 |
p. 403-409 |
artikel |
26 |
Response to request for Corrigendum to “Efficacy and safety of an inactivated vaccine against Salmonid alphavirus (family Togaviridae)”. [Vaccine 30(38) (2012) 5688–5694]
|
Karlsen, Marius |
|
|
35 |
2 |
p. 204 |
artikel |
27 |
Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study
|
Frenck Jr, Robert W. |
|
|
35 |
2 |
p. 375-384 |
artikel |
28 |
Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial
|
Creech, C. Buddy |
|
|
35 |
2 |
p. 385-394 |
artikel |
29 |
Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains
|
Zhou, Hui |
|
|
35 |
2 |
p. 305-312 |
artikel |
30 |
Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model
|
Xu, Qingfu |
|
|
35 |
2 |
p. 337-344 |
artikel |
31 |
When should a time at risk start in efficacy malaria vaccine trials?
|
Ejigu, Dawit Asmamaw |
|
|
35 |
2 |
p. 201 |
artikel |